立方制药 (003020.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

14.7x

Market Cap

CNY 3.99B

MomentumView details →

1D Return

−3.64%

YTD Return

−31.57%

RSI (14)

45.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

14.7x

Market Cap

CNY 3.99B

RSI (14)

45.9

MomentumView details →

1D Return

−3.64%

YTD Return

−31.57%

ProfitabilityView details →

Gross Margin

65.18%

Net Margin

10.46%

EBITDA Margin

17.38%

ROE (TTM)

8.80%

ROA (TTM)

6.12%

Asset Turnover

0.59x

GrowthView details →

Revenue YoY

+0.36%

EPS YoY

−2.77%

FCF YoY

+64.51%

Revenue CAGR 3Y

−15.54%

EPS CAGR 3Y

−13.19%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.04x

Current Ratio

2.28x

Quick Ratio

1.86x

Div Yield

3.16%

Div Rate

CNY 0.56

Div Growth 1Y

−48.57%

Financials snapshotView financials →

Revenue (TTM)

1.55B

Net Income (TTM)

162.24M

Op. CF (TTM)

240.49M

Latest newsMore news →

Lifang Pharmaceutical announced that its doxazosin mesylate extended-release tablets and azilsartan medoxomil potassium tablets are proposed to be selected in the 12th batch of China's national centralized drug procurement, with the procurement cycle lasting until December 31, 2029.33d ago

Lifang Pharmaceutical announced that 4 of its drug varieties were newly included in the National Essential Drug List (2026 edition).57d ago

Similar companies

华帝股份002035.SZ 福恩股份001312.SZ 森鹰窗业301227.SZ 金河生物002688.SZ 天邑股份300504.SZ 华茂股份000850.SZ Find similar companies →

Latest newsMore news →

Lifang Pharmaceutical announced that its doxazosin mesylate extended-release tablets and azilsartan medoxomil potassium tablets are proposed to be selected in the 12th batch of China's national centralized drug procurement, with the procurement cycle lasting until December 31, 2029.33d ago Lifang Pharmaceutical announced that 4 of its drug varieties were newly included in the National Essential Drug List (2026 edition).57d ago